The recent NHANES III United States survey of ~17,000 subjects without apparent thyroid disease, reported detectable TPOAb levels in 12 % of subjects using a competitive immunoassay method.

Discover OncoCyte's Q4 2024 progress with its cutting-edge kidney transplant test. Insights on FDA ambitions, market strategies & financial runway.

can compete with free hormone for a limited number of antibody-binding sites in a classical competitive immunoassay format. Though conceptually attractive, this approach is technically difficult ...

Q4 2024 Earnings Call Transcript March 24, 2025 OncoCyte Corporation misses on earnings expectations. Reported EPS is ...

Drill hole LC-24-122 returned 2.62 g/t Au over 41.1 meters starting at a depth of 51.8 meters including an intercept of 6.81 ...

The "Molecular Diagnostics Patent Landscape Report" report has been added to ResearchAndMarkets.com's offering. The global ...

NANO Nuclear Energy Inc. (NASDAQ: NNE) ("NANO Nuclear” or "the Company”), a leading advanced nuclear energy and technology ...

Terrestrial Energy to Become First Publicly Traded Molten Salt Nuclear Reactor Developer Through Combination with HCM II ...

EU Profunda underground channel samples return high grades, including: 27 samples averaging 3.62% Cu, 0.17% Co, 0.09% Ni, ...

The Company recognized $5.8 million in grant revenue in the year ending December 31, 2024 and $4.9 million for the year ending December 31, 2023, which in both periods represents CPRIT’s share of the ...